.
MergerLinks Header Logo

Announced

Completed

RA Capital Management and Nextech Invest led a $105m Series B round in Boundless Bio.

Financials

Edit Data
Transaction Value£75m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Majority

Friendly

Private Equity

United States

Biotechnology

Domestic

Completed

oncology company

Acquisition

Venture Capital

Private

Synopsis

Edit

RA Capital Management and Nextech Invest led a $105m Series B round in Boundless Bio, a next-generation precision oncology company, with participation from Fidelity Management & Research Company, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, Logos Capital, ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital and Alexandria Venture Investments. "RA Capital has been following the Boundless Bio story for some time now and believes that the team has developed industry-leading expertise in the biology that underlies high unmet need, gene amplified tumors," Zach Scheiner, RA Capital Management Principal.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US